Incyte (INCY) and Edison Scientific announced a strategic collaboration to employ Kosmos, Edison’s AI scientist, for Incyte’s discovery and development work. Kosmos will be embedded across the Incyte discovery and development lifecycle, enabling continuous learning from translational and clinical data, real-time synthesis of evidence and predictive models of therapeutic performance.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte Targets KRAS G12D Pancreatic Cancer With New Phase 3 DAWN-303 Trial
- Incyte announces 24-week long-term data from Phase 3 TRuE-AD4 trial
- Incyte gets orphan designation for treatment of pancreatic cancer
- MacroGenics, Sagard enter expanded Zynyz royalty purchase agreement
- Incyte announces FDA approval of Jakari XR